Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals

  • US 8,791,140 B2
  • Filed: 03/25/2008
  • Issued: 07/29/2014
  • Est. Priority Date: 04/05/2007
  • Status: Active Grant
First Claim
Patent Images

1. A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ

  • ) of 6.0±

    0.1 and further comprising at least one peak at diffraction angle (2θ

    ) selected from 11.5±

    0.1, 21.0±

    0.1 and 26.9±

    0.1.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×